# US 2024/0350668 A1 · Pharmaceutical composition utilizing bornavirus vector

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0350668 A1
- Document ID: US20240350668A1
- Status: Published application
- Kind: A1
- Application number: 18/688,563
- Filed: 2022-08-31
- Published: 2024-10-24
- Earliest claimed: 2021-09-02
- Assignees: Kyoto University; National University Corporation Shiga University of Medical Science
- Applicants: Kyoto University; National University Corporation Shiga University of Medical Science
- Inventors: Keizo TOMONAGA; Akiko MAKINO; Madoka SAKAI; Ryo KOMORIZONO; Makoto URUSHITANI; Toshifumi MORIMURA; Sumio MINAMIYAMA
- Web page: https://patentgrep.com/patent/US20240350668A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/005: from viruses
- C07K 16/40: against enzymes
- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- C12N 15/86: Viral vectors
- A61K 2039/505: {comprising antibodies}
- A61K 2039/53: {DNA (RNA) vaccination}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2510/00: Genetically modified cells
- C12N 2760/00043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are a bornavirus vector comprising a nucleic acid encoding an antibody or antibody fragment capable of binding to a mutant SOD1 protein, the antibody or antibody fragment comprising a heavy-chain variable region comprising a heavy-chain CDR1 consisting of an amino acid sequence GFSLNTSGMG (SEQ ID NO: 1), a heavy-chain CDR2 consisting of an amino acid sequence IWWDDDK (SEQ ID NO: 2), and a heavy-chain CDR3 consisting of an amino acid sequence ARLGYAMDY (SEQ ID NO: 3), the heavy-chain variable region optionally having 3 or fewer amino acid substitutions, and/or a light-chain variable region comprising a light-chain CDR1 consisting of an amino acid sequence ONVGTN (SEQ ID NO: 4), a light-chain CDR2 consisting of an amino acid sequence SAS, and a light-chain CDR3 consisting of an amino acid sequence QQYYIYPYT (SEQ ID NO: 5), the light-chain variable region optionally having 3 or fewer amino acid substitutions; a recombinant virus comprising RNA encoded by the bornavirus vector; a cell infected with the recombinant virus; and a pharmaceutical composition comprising the cell.

## Claims

### Claim 1

A bornavirus vector comprising a nucleic acid encoding an antibody or antibody fragment capable of binding to a mutant SOD1 protein,
the antibody or antibody fragment comprising:
a heavy-chain variable region comprising a heavy-chain CDR1 consisting of an amino acid sequence GFSLNTSGMG (SEQ ID NO: 1), a heavy-chain CDR2 consisting of an amino acid sequence IWWDDDK (SEQ ID NO: 2), and a heavy-chain CDR3 consisting of an amino acid sequence ARLGYAMDY (SEQ ID NO: 3), the heavy-chain variable region optionally having 3 or fewer amino acid substitutions; and/or
a light-chain variable region comprising a light-chain CDR1 consisting of an amino acid sequence QNVGTN (SEQ ID NO: 4), a light-chain CDR2 consisting of an amino acid sequence SAS, and a light-chain CDR3 consisting of an amino acid sequence QQYYIYPYT (SEQ ID NO: 5), the light-chain variable region optionally having 3 or fewer amino acid substitutions.

### Claim 2 (depends on 1)

The bornavirus vector according to claim 1, wherein the antibody fragment is a Fab, Fab′, F(ab′)2, Fv, scFv, scFab, dsFv, ds-scFv, diabody, triabody, tetrabody, or minibody.

### Claim 3 (depends on 1)

The bornavirus vector according to claim 1, wherein the antibody fragment is an scFv.

### Claim 4 (depends on 1)

The bornavirus vector according to claim 1, wherein the antibody or antibody fragment is a humanized antibody or antibody fragment.

### Claim 5 (depends on 1)

The bornavirus vector according to claim 1, comprising:
(a) cDNA of recombinant viral RNA having at least the N gene, X gene, P gene, and L gene of a Borna disease virus genome in the same order as in the Borna disease virus genome and having a sequence in which the nucleic acid is inserted into the untranslated region ligated downstream of the coding region of the P gene;
(b) DNA encoding a ribozyme; and
(c) a promoter sequence,
wherein (b) is located upstream and downstream of (a), and (a) and (b) are located downstream of (c).

### Claim 6 (depends on 1)

A recombinant virus comprising RNA encoded by the bornavirus vector of claim 1.

### Claim 7 (depends on 6)

A cell into which the nucleic acid has been introduced by infection with the recombinant virus of claim 6.

### Claim 8 (depends on 7)

The cell according to claim 7, wherein the cell is an oligodendrocyte progenitor cell, glial neural progenitor cell, dopamine neural progenitor cell, microglia, neural progenitor cell, neural stem cell, mesenchymal stem cell, Muse cell, iPS cell, or ES cell.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 7)

A method for treating the disease in which mutant SOD1 accumulates, comprising administering an effective amount of the cell of claim 7 to a mammal.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the disease in which mutant SOD1 accumulates is amyotrophic lateral sclerosis.
